PadmaneeSharmaMD

Oncology • Houston, TX

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Join to view full profile

Are you Dr. Sharma?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 94 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Dr. Padmanee Sharma, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Florida, and Oklahoma. She is affiliated with University of Texas M.D. Anderson Cancer Center and is a Professor at Division of Cancer Medicine.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2000
Pennsylvania State University College of MedicineClass of 1998

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2004 - 2026
OK State Medical License 2020 - 2021
NY State Medical License 1999 - 2005

Clinical Trials

NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Start of enrollment: 2004 Sep 27
Completed
Phase 1
Neoadjuvant Ipilimumab in Prostate Cancer Start of enrollment: 2010 Sep 01
Completed
Phase 2
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer Start of enrollment: 2014 Apr 22
Completed
Phase 2
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2014 Aug 20
Completed
Early Phase 1
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery Start of enrollment: 2014 Nov 25
Active, not recruiting
Early Phase 1
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2016 Mar 30
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

Next-generation combination approaches for immune checkpoint therapy.
Sangeeta Goswami, Kristen E Pauken, Linghua Wang, Padmanee Sharma
Nature Immunology. 2024-12-01
Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cel...
Sangeeta Goswami, Jianjun Gao, Sreyashi Basu, Daniel D Shapiro, Jose A Karam
Research Square. 2024-11-12
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.
Michael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, Lianchun Xiao, Elshad Hasanov
Oncology. 2024-10-18

Press Mentions

Allison Institute Scientific Symposium Features Spatial Biology Breakthroughs, $5 Million Gift to Support Further EffortsOctober 14th, 2024
MD Anderson Research Highlights for September 4, 2024September 4th, 2024
MD Anderson Research Highlights for July 24, 2024July 24th, 2024
Join now to see all